Tuesday 27 October 2026 Export LLY’s income statement to Excel — free account

Eli Lilly and Company

LLY Healthcare Drug Manufacturers General

Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 26.2%, free cash flow grew 458.1% and total debt rose 37.6%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years, revenue growth for five.

1,279.14 5.68 +0.45%

Follow LLY

Alert me

Market cap: $1.20T
P/E: 42.9×
Fwd P/E: 36.7×
Dividend yield: 0.52%
F-score: 7/9
Altman Z: 8.61
Beneish M: −1.91
Dividend safety: 86/100

Overview Business Profile Earnings & Analysis Segments Filings

Eli Lilly and Company (LLY) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2025: revenue by segment, and margins
Reportable Segment	65,179	100.00%
Gross margin		83.04%
Operating margin		40.35%
Pre-tax margin		39.48%

Revenue by segment $m

Line	FY2025	FY2024	FY2023	FY2022	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011
Reportable Segment	65,179 100.00%	45,043 100.00%	34,124 100.00%	28,541 100.00%	—	—	—	—	—	—	—
Animal Health Products	—	—	—	—	3,086 15.45%	3,158 14.88%	3,181 15.94%	2,347 11.96%	2,152 9.31%	2,037 9.01%	1,679 6.91%
Endocrinology	—	—	—	—	—	—	—	—	7,304 31.60%	6,811 30.13%	6,807 28.03%
Neuroscience	—	—	—	—	—	—	—	—	7,216 31.22%	7,575 33.51%	9,724 40.04%
Oncology	—	—	—	—	—	—	—	—	3,269 14.14%	3,282 14.52%	3,322 13.68%
Cardiovascular	—	—	—	—	—	—	—	—	2,923 12.65%	2,633 11.65%	2,486 10.24%
Other Pharmaceuticals	—	—	—	—	—	—	—	—	249 1.08%	267 1.18%	269 1.11%
Eliminations	—	—	—	—	(2,897) (14.51%)	—	—	—	—	—	—
Human Pharmaceutical Products	—	—	—	—	—	—	—	—	20,962	20,567	22,608
Revenue	65,179	45,043	34,124	28,541	19,974	21,222	19,959	19,616	23,113	22,603	24,287

Gross profit by segment $m, and margin

	FY2025	FY2024	FY2023	FY2022	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011
Reportable Segment	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Gross profit	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

Revenue by region $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010
U.S.	43,481 66.71%	30,375 67.44%	21,791 63.86%	18,190 63.73%	16,811 59.36%	14,229 57.98%	12,723 57.00%	12,392 57.65%	11,414 57.15%	11,506 54.22%	10,097 50.59%	9,134 46.57%	12,890 55.77%	12,313 54.47%	12,977 53.43%	12,866 55.75%
Europe	11,558 17.73%	6,921 15.37%	6,175 18.10%	4,299 15.06%	4,777 16.87%	4,188 17.06%	3,765 16.87%	3,663 17.04%	3,391 16.98%	3,768 17.76%	3,944 19.76%	4,507 22.98%	4,338 18.77%	4,260 18.85%	5,291 21.79%	5,106 22.13%
Rest of world	6,057 9.29%	4,271 9.48%	2,946 8.63%	2,852 9.99%	2,702 9.54%	2,423 9.87%	2,345 10.51%	2,280 10.61%	2,829 14.17%	3,617 17.04%	3,885 19.46%	3,948 20.13%	3,821 16.53%	3,784 16.74%	3,914 16.12%	3,487 15.11%
Japan	2,132 3.27%	1,815 4.03%	1,673 4.90%	1,747 6.12%	2,367 8.36%	2,583 10.53%	2,548 11.41%	2,407 11.20%	2,340 11.71%	2,331 10.98%	2,033 10.19%	2,027 10.33%	2,064 8.93%	2,246 9.94%	2,104 8.66%	1,617 7.01%
China	1,951 2.99%	1,660 3.69%	1,540 4.51%	1,453 5.09%	1,661 5.87%	1,117 4.55%	939 4.21%	751 3.49%	—	—	—	—	—	—	—	—
Outside U.S.	21,698	14,668	12,333	10,351	11,507	10,311	9,597	9,101	8,559	9,716	—	—	—	—	—	—
Revenue	65,179	45,043	34,124	28,541	28,318	24,540	22,320	21,493	19,974	21,222	19,959	19,616	23,113	22,603	24,287	23,076

Operating figures as reported in each quarter’s results release or filing

Figure	Quarter	Latest	A year before	Change
U.S. volume increase	Q2 FY2026	37.0%	46.0%	—
Volume increase outside the U.S.	Q2 FY2026	113.0%	35.0%	—
Worldwide volume increase	Q2 FY2026	60.0%	42.0%	—

	Q2 FY2026	Q1 FY2026	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025	Q4 FY2024	Q3 FY2024	Q2 FY2024	Q1 FY2024
U.S. volume increase	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Volume increase outside the U.S.	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Worldwide volume increase	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.